DE60030723D1 - Substanziell kristalline form von melagatran - Google Patents

Substanziell kristalline form von melagatran

Info

Publication number
DE60030723D1
DE60030723D1 DE60030723T DE60030723T DE60030723D1 DE 60030723 D1 DE60030723 D1 DE 60030723D1 DE 60030723 T DE60030723 T DE 60030723T DE 60030723 T DE60030723 T DE 60030723T DE 60030723 D1 DE60030723 D1 DE 60030723D1
Authority
DE
Germany
Prior art keywords
melagatrane
substancial
crystalline form
crystalline
substancial crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60030723T
Other languages
English (en)
Other versions
DE60030723T2 (de
Inventor
Lena Hedstroem
Anita Lundblad
Sofia Nagard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of DE60030723D1 publication Critical patent/DE60030723D1/de
Application granted granted Critical
Publication of DE60030723T2 publication Critical patent/DE60030723T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Liquid Crystal Substances (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
DE60030723T 1999-07-02 2000-06-30 Substanziell kristalline form von melagatran Expired - Lifetime DE60030723T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9902550A SE9902550D0 (sv) 1999-07-02 1999-07-02 New crystalline forms
SE9902550 1999-07-02
PCT/SE2000/001398 WO2001002426A1 (en) 1999-07-02 2000-06-30 A substantially crystalline form of melagatran

Publications (2)

Publication Number Publication Date
DE60030723D1 true DE60030723D1 (de) 2006-10-26
DE60030723T2 DE60030723T2 (de) 2007-11-08

Family

ID=20416364

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60030723T Expired - Lifetime DE60030723T2 (de) 1999-07-02 2000-06-30 Substanziell kristalline form von melagatran

Country Status (33)

Country Link
US (1) US6479078B1 (de)
EP (1) EP1196431B1 (de)
JP (1) JP2003503508A (de)
KR (1) KR20020020765A (de)
CN (1) CN100537598C (de)
AR (1) AR035553A1 (de)
AT (1) ATE339438T1 (de)
AU (1) AU765614B2 (de)
BR (1) BR0012035A (de)
CA (1) CA2376944A1 (de)
CY (1) CY1107542T1 (de)
CZ (1) CZ20014722A3 (de)
DE (1) DE60030723T2 (de)
DK (1) DK1196431T3 (de)
EE (1) EE200100646A (de)
ES (1) ES2270849T3 (de)
HK (1) HK1045529B (de)
HU (1) HUP0202322A3 (de)
IL (1) IL146972A0 (de)
IS (1) IS6215A (de)
MX (1) MXPA01013441A (de)
MY (1) MY122760A (de)
NO (1) NO20016419L (de)
NZ (1) NZ516187A (de)
PL (1) PL352872A1 (de)
PT (1) PT1196431E (de)
RU (1) RU2243973C2 (de)
SE (1) SE9902550D0 (de)
SK (1) SK18832001A3 (de)
TR (1) TR200103855T2 (de)
TW (1) TWI250991B (de)
WO (1) WO2001002426A1 (de)
ZA (1) ZA200109944B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6976012B1 (en) 2000-01-24 2005-12-13 Sony Corporation Method and apparatus of using a neural network to train a neural network
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
US7129233B2 (en) * 2000-12-01 2006-10-31 Astrazeneca Ab Mandelic acid derivatives and their use as thrombin inhibitors
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
SE0201659D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
SE0201661D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab New salts
US7781424B2 (en) * 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
CA2547625C (en) * 2003-11-27 2012-07-24 Ajinomoto Co., Inc. Crystals of phenylalanine derivatives and production methods thereof
US20050209211A1 (en) * 2004-03-16 2005-09-22 Devalina Law Trihemihydrate, anhydrate and novel hydrate forms of Cefdinir
US7524354B2 (en) * 2005-07-07 2009-04-28 Research Foundation Of State University Of New York Controlled synthesis of highly monodispersed gold nanoparticles
TW200827336A (en) * 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
US20090061000A1 (en) * 2007-08-31 2009-03-05 Astrazeneca Ab Pharmaceutical formulation use 030

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0687881A (ja) * 1992-09-07 1994-03-29 Asahi Chem Ind Co Ltd ロキタマイシン・一水和物結晶、及びその製造法
JP3077925B2 (ja) * 1992-12-15 2000-08-21 ヤマサ醤油株式会社 ２’−デオキシ−２’−メチリデンシチジン無水物結晶およびその製造法
SE9301916D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
JP3182685B2 (ja) * 1995-09-01 2001-07-03 北陸製薬株式会社 水和物結晶及びその製造方法
JP2914324B2 (ja) * 1995-10-23 1999-06-28 味の素株式会社 ピペリジン誘導体の結晶並びにその製造中間体及び製造方法
TW541316B (en) * 1995-12-21 2003-07-11 Astrazeneca Ab Prodrugs of thrombin inhibitors
SE9603724D0 (sv) * 1996-10-11 1996-10-11 Astra Ab New pharmaceutical parenteral formulation of a thrombin inhibitor
SE9802974D0 (sv) 1998-09-03 1998-09-03 Astra Ab New crystalline forms
FR2793418B1 (fr) * 1999-05-11 2001-07-27 Synthelabo Formulations galeniques d'agents antithrombotiques pour administration sous-cutanee

Also Published As

Publication number Publication date
HUP0202322A2 (en) 2002-10-28
NO20016419L (no) 2002-03-01
RU2243973C2 (ru) 2005-01-10
SE9902550D0 (sv) 1999-07-02
NO20016419D0 (no) 2001-12-28
JP2003503508A (ja) 2003-01-28
EE200100646A (et) 2003-02-17
HUP0202322A3 (en) 2003-04-28
MXPA01013441A (es) 2002-07-02
KR20020020765A (ko) 2002-03-15
CY1107542T1 (el) 2013-03-13
TWI250991B (en) 2006-03-11
ATE339438T1 (de) 2006-10-15
WO2001002426A1 (en) 2001-01-11
US6479078B1 (en) 2002-11-12
PT1196431E (pt) 2007-01-31
EP1196431B1 (de) 2006-09-13
HK1045529B (zh) 2007-02-23
AU765614B2 (en) 2003-09-25
ES2270849T3 (es) 2007-04-16
IL146972A0 (en) 2002-08-14
DE60030723T2 (de) 2007-11-08
IS6215A (is) 2001-12-27
AU6040800A (en) 2001-01-22
CZ20014722A3 (cs) 2002-05-15
CN100537598C (zh) 2009-09-09
BR0012035A (pt) 2002-03-19
PL352872A1 (en) 2003-09-08
MY122760A (en) 2006-05-31
CA2376944A1 (en) 2001-01-11
DK1196431T3 (da) 2006-12-11
SK18832001A3 (sk) 2002-10-08
ZA200109944B (en) 2003-03-03
AR035553A1 (es) 2004-06-16
CN1359389A (zh) 2002-07-17
NZ516187A (en) 2004-09-24
HK1045529A1 (en) 2002-11-29
EP1196431A1 (de) 2002-04-17
TR200103855T2 (tr) 2002-04-22

Similar Documents

Publication Publication Date Title
DK1261585T3 (da) Substituerede indol-Mannichbaser
PT1181017E (pt) Inibidores de metaloproteases
DE60042550D1 (de) Mutierte varianten des insulin-ähnlichen wachstumsfaktor i (igf-i)
DK1175408T3 (da) Pyrimidinonforbindelser
NO20015536L (no) FAP-aktiverte anti-tumor-forbindelser
EE200200224A (et) Uudsed ühendid
ID30233A (id) Antibiotika ketolida
PT1194404E (pt) Inibidores de aspartil-protease
NO20020030L (no) Krystallinske 1-metylkarbapenemforbindelser
ATE261431T1 (de) Kristalline form von (s)-2-ethoxy-3-4-(2-4- methansulfonyloxyphenyl-ethoxy)phenyl)propansäu e
DE60030723D1 (de) Substanziell kristalline form von melagatran
ATE386501T1 (de) Formulierungen von wachstumshormonen
DE60032726D1 (de) OPTISCHES ZEITBEREICHSREFLEkTOMETER
ATE276325T1 (de) Haftklebstoffe
DE60024400D1 (de) Empfangsgerät
DE60107074D1 (de) Kristallin form ii von cabergolin
PT1175417E (pt) Compostos substituidos de benzolactamas
DE69940563D1 (de) Wachstum von aluminium-einkristallen
PT1232141E (pt) Eteres de o-desmetil-venlafaxina
DK1226125T3 (da) Fremgangsmåde til fremstilling af mavesårsmidler
DE29903141U1 (de) Zeitschaltuhr
DE29902506U1 (de) Mauerstein
EE200200053A (et) Isoretinoiini valmistamise protsess
DE69942093D1 (de) Verwaltungsschema von Rundsendung
DK1191025T3 (da) Krystaller af lansoprazol

Legal Events

Date Code Title Description
8364 No opposition during term of opposition